Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?

Journal of Hepatology

Volumn 68, Issue 2, 2018, Pages 335-352

  Lonardo, Amedeo ^a   Nascimbeni, Fabio ^a   Mantovani, Alessandro ^b   Targher, Giovanni ^b  

^a Az Ospedaliero Universitaria   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Cardiovascular disease; Diabetes; Hypertension; NAFLD; NASH

Indexed keywords

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; INTESTINE; LIPIDOMICS; LIVER; MORBIDITY; MORTALITY; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; DISEASE MANAGEMENT; PREVALENCE; RISK FACTOR;

ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMANS; HYPERTENSION; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RISK FACTORS;

EID: 85033235490     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.09.021     Document Type: Review

References (216)

1. European Association for the Study of the L European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1388–1402.
2. Italian Association for the Study of the L. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis 49 (2017), 471–483.
3. Younossi, Z.M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64 (2016), 1577–1586.
4. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
5. Ekstedt, M., Hagstrom, H., Nasr, P., Fredrikson, M., Stal, P., Kechagias, S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
6. Targher, G., Byrne, C.D., Lonardo, A., Zoppini, G., Barbui, C., Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol 65 (2016), 589–600.
7. Yki-Jarvinen, H., Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2 (2014), 901–910.
8. Wainwright, P., Byrne, C.D., Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome. Int J Mol Sci, 17, 2016, 367.
9. Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., Loria, P., Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 47 (2015), 181–190.
10. Hamaguchi, M., Kojima, T., Takeda, N., Nakagawa, T., Taniguchi, H., Fujii, K., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143 (2005), 722–728.
11. Tsuneto, A., Hida, A., Sera, N., Imaizumi, M., Ichimaru, S., Nakashima, E., et al. Fatty liver incidence and predictive variables. Hypertens Res 33 (2010), 638–643.
12. Sorrentino, P., Terracciano, L., D'Angelo, S., Ferbo, U., Bracigliano, A., Vecchione, R., Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol 105 (2010), 336–344.
13. Zhang, T., Zhang, C., Zhang, Y., Tang, F., Li, H., Zhang, Q., et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. Atherosclerosis 240 (2015), 144–148.
14. Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654 [e641–e649; quiz e639–640].
15. Adams, L.A., Waters, O.R., Knuiman, M.W., Elliott, R.R., Olynyk, J.K., NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 104 (2009), 861–867.
16. Lau, K., Lorbeer, R., Haring, R., Schmidt, C.O., Wallaschofski, H., Nauck, M., et al. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J Hypertens 28 (2010), 1829–1835.
17. Vanni, E., Bugianesi, E., Kotronen, A., De Minicis, S., Yki-Jarvinen, H., Svegliati-Baroni, G., From the metabolic syndrome to NAFLD or vice versa?. Dig Liver Dis 42 (2010), 320–330.
18. Sung, K.C., Jeong, W.S., Wild, S.H., Byrne, C.D., Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 35 (2012), 717–722.
19. Park, S.K., Seo, M.H., Shin, H.C., Ryoo, J.H., Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 57 (2013), 1378–1383.
20. Ryoo, J.H., Ham, W.T., Choi, J.M., Kang, M.A., An, S.H., Lee, J.K., et al. Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension. J Korean Med Sci 29 (2014), 973–979.
21. Ryoo, J.H., Suh, Y.J., Shin, H.C., Cho, Y.K., Choi, J.M., Park, S.K., Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol 29 (2014), 1926–1931.
22. Ballestri, S., Zona, S., Targher, G., Romagnoli, D., Baldelli, E., Nascimbeni, F., et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 31 (2016), 936–944.
23. Hashimoto, Y., Hamaguchi, M., Fukuda, T., Ohbora, A., Kojima, T., Fukui, M., Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals. Endocrine 57 (2017), 89–97.
24. Sung, K.C., Wild, S.H., Byrne, C.D., Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 98 (2013), 3637–3643.
25. Sung, K.C., Wild, S.H., Byrne, C.D., Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol 60 (2014), 1040–1045.
26. Yamazaki, H., Tsuboya, T., Tsuji, K., Dohke, M., Maguchi, H., Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care 38 (2015), 1673–1679.
27. Zhang, Y., Zhang, T., Zhang, C., Tang, F., Zhong, N., Li, H., et al. Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open, 5, 2015, e008204.
28. Ballestri, S., Nascimbeni, F., Romagnoli, D., Lonardo, A., The independent predictors of non-alcoholic steatohepatitis and its individual histological features: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res 46 (2016), 1074–1087.
29. Ma, J., Hwang, S.J., Pedley, A., Massaro, J.M., Hoffmann, U., Chung, R.T., et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol 66 (2017), 390–397.
30. Li, Y., Wang, J., Tang, Y., Han, X., Liu, B., Hu, H., et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study. PLoS One, 12, 2017, e0174291.
31. Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Bohm, M., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
32. Ferrannini, E., Cushman, W.C., Diabetes and hypertension: the bad companions. Lancet 380 (2012), 601–610.
33. Lopez-Suarez, A., Guerrero, J.M., Elvira-Gonzalez, J., Beltran-Robles, M., Canas-Hormigo, F., Bascunana-Quirell, A., Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol 23 (2011), 1011–1017.
34. Qian, L.Y., Tu, J.F., Ding, Y.H., Pang, J., Che, X.D., Zou, H., et al. Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population: Normal is not the new normal. Medicine, 95, 2016, e4293.
35. Lorbeer, R., Bayerl, C., Auweter, S., Rospleszcz, S., Lieb, W., Meisinger, C., et al. Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease. J Hypertens 35 (2017), 737–744.
36. Long, M.T., Wang, N., Larson, M.G., Mitchell, G.F., Palmisano, J., Vasan, R.S., et al. Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study. Arterioscler Thromb Vasc Biol 35 (2015), 1284–1291.
37. Aneni, E.C., Oni, E.T., Martin, S.S., Blaha, M.J., Agatston, A.S., Feldman, T., et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens 33 (2015), 1207–1214.
38. Bonapace, S., Perseghin, G., Molon, G., Canali, G., Bertolini, L., Zoppini, G., et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35 (2012), 389–395.
39. Hallsworth, K., Hollingsworth, K.G., Thoma, C., Jakovljevic, D., MacGowan, G.A., Anstee, Q.M., et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol 58 (2013), 757–762.
40. VanWagner, L.B., Wilcox, J.E., Colangelo, L.A., Lloyd-Jones, D.M., Carr, J.J., Lima, J.A., et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 62 (2015), 773–783.
41. Petta, S., Argano, C., Colomba, D., Camma, C., Di Marco, V., Cabibi, D., et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol 62 (2015), 928–933.
42. Targher, G., Chonchol, M., Zoppini, G., Abaterusso, C., Bonora, E., Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?. J Hepatol 54 (2011), 1020–1029.
43. Musso, G., Gambino, R., Tabibian, J.H., Ekstedt, M., Kechagias, S., Hamaguchi, M., et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med, 11, 2014, e1001680.
44. Targher, G., Byrne, C.D., Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol 13 (2017), 297–310.
45. Liccardo, D., Mosca, A., Petroni, S., Valente, P., Giordano, U., Mico, A.G., et al. The association between retinal microvascular changes, metabolic risk factors, and liver histology in pediatric patients with non-alcoholic fatty liver disease (NAFLD). J Gastroenterol 50 (2015), 903–912.
46. Romero-Ibarguengoitia, M.E., Herrera-Rosas, A., Dominguez-Mota, A.A., Camas-Benitez, J.T., Serratos-Canales, M.F., Leon-Hernandez, M., et al. Nonalcoholic fatty liver disease can be predicted by retinal vascular changes in patients with obesity without hypertension or diabetes. Eur J Gastroenterol Hepatol 29 (2017), 962–967.
47. Ballestri, S., Lonardo, A., Bonapace, S., Byrne, C.D., Loria, P., Targher, G., Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20 (2014), 1724–1745.
48. Valbusa, F., Bonapace, S., Agnoletti, D., Scala, L., Grillo, C., Arduini, P., et al. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS One, 12, 2017, e0173398.
49. Wu, S.J., Zou, H., Zhu, G.Q., Wang, L.R., Zhang, Q., Shi, K.Q., et al. Increased levels of systolic blood pressure within the normal range are associated with significantly elevated risks of nonalcoholic fatty liver disease. Medicine, 94, 2015, e842.
50. Stranges, S., Trevisan, M., Dorn, J.M., Dmochowski, J., Donahue, R.P., Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study. Hypertension 46 (2005), 1186–1193.
51. Huh, J.H., Ahn, S.V., Koh, S.B., Choi, E., Kim, J.Y., Sung, K.C., et al. A prospective study of fatty liver index and incident hypertension: the KoGES-ARIRANG study. PLoS One, 10, 2015, e0143560.
52. Bonnet, F., Gastaldelli, A., Pihan-Le Bars, F., Natali, A., Roussel, R., Petrie, J., et al. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. J Hypertens 35 (2017), 493–500.
53. Li, N., Zhang, G.W., Zhang, J.R., Jin, D., Li, Y., Liu, T., et al. Non-alcoholic fatty liver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis 25 (2015), 218–223.
54. Takase, H., Dohi, Y., Toriyama, T., Okado, T., Tanaka, S., Sonoda, H., et al. Brachial-ankle pulse wave velocity predicts increase in blood pressure and onset of hypertension. Am J Hypertens 24 (2011), 667–673.
55. Kaess, B.M., Rong, J., Larson, M.G., Hamburg, N.M., Vita, J.A., Levy, D., et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 308 (2012), 875–881.
56. Zheng, X., Jin, C., Liu, Y., Zhang, J., Zhu, Y., Kan, S., et al. Arterial stiffness as a predictor of clinical hypertension. J Clin Hypertens 17 (2015), 582–591.
57. Non-alcoholic Fatty Liver Disease Study G, Lonardo, A., Bellentani, S., Argo, C.K., Ballestri, S., Byrne, C.D., Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 47 (2015), 997–1006.
58. Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30 (2007), 1212–1218.
59. Anstee, Q.M., Targher, G., Day, C.P., Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10 (2013), 330–344.
60. Byrne, C.D., Targher, G., NAFLD: a multisystem disease. J Hepatol 62 (2015), S47–64.
61. McPherson, S., Hardy, T., Henderson, E., Burt, A.D., Day, C.P., Anstee, Q.M., Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62 (2015), 1148–1155.
62. Doycheva, I., Cui, J., Nguyen, P., Costa, E.A., Hooker, J., Hofflich, H., et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther 43 (2016), 83–95.
63. Kwok, R., Choi, K.C., Wong, G.L., Zhang, Y., Chan, H.L., Luk, A.O., et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 65 (2016), 1359–1368.
64. Castera, L., Vilgrain, V., Angulo, P., Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 10 (2013), 666–675.
65. Bazick, J., Donithan, M., Neuschwander-Tetri, B.A., Kleiner, D., Brunt, E.M., Wilson, L., et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care 38 (2015), 1347–1355.
66. Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 100 (2015), 2231–2238.
67. Zoppini, G., Fedeli, U., Gennaro, N., Saugo, M., Targher, G., Bonora, E., Mortality from chronic liver diseases in diabetes. Am J Gastroenterol 109 (2014), 1020–1025.
68. Wild, S.H., Morling, J.R., McAllister, D.A., Kerssens, J., Fischbacher, C., Parkes, J., et al. Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. J Hepatol 64 (2016), 1358–1364.
69. Porepa, L., Ray, J.G., Sanchez-Romeu, P., Booth, G.L., Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 182 (2010), E526–E531.
70. Baffy, G., Brunt, E.M., Caldwell, S.H., Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 56 (2012), 1384–1391.
71. Michelotti, G.A., Machado, M.V., Diehl, A.M., NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 10 (2013), 656–665.
72. Marengo, A., Rosso, C., Bugianesi, E., Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 67 (2016), 103–117.
73. Singh, S., Singh, P.P., Singh, A.G., Murad, M.H., Sanchez, W., Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 108 (2013), 881–891 [Quiz 892].
74. Targher, G., Bertolini, L., Padovani, R., Rodella, S., Zoppini, G., Pichiri, I., et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 53 (2010), 713–718.
75. Sviklane, L., Olmane, E., Dzerve, Z., Kupcs, K., Pirags, V.V., Sokolovska, J., Fatty liver index and hepatic steatosis index predict non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol, 2017, 10.1111/jgh.13814 [Epub ahead of print].
76. Harman, D.J., Kaye, P.V., Harris, R., Suzuki, A., Gazis, A., Aithal, G.P., Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes. Hepatology 60 (2014), 158–168.
77. Targher, G., Marchesini, G., Byrne, C.D., Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?. Diabetes Metab 42 (2016), 142–156.
78. Chen, S.C., Tsai, S.P., Jhao, J.Y., Jiang, W.K., Tsao, C.K., Chang, L.Y., Liver fat, hepatic enzymes, alkaline phosphatase and the risk of incident type 2 Diabetes: a prospective study of 132,377 adults. Sci Rep, 7, 2017, 4649.
79. Bae, J.C., Rhee, E.J., Lee, W.Y., Park, S.E., Park, C.Y., Oh, K.W., et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 34 (2011), 727–729.
80. Shibata, M., Kihara, Y., Taguchi, M., Tashiro, M., Otsuki, M., Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 30 (2007), 2940–2944.
81. Chang, Y., Jung, H.S., Yun, K.E., Cho, J., Cho, Y.K., Ryu, S., Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 108 (2013), 1861–1868.
82. Bjorkstrom, K., Stal, P., Hultcrantz, R., Hagstrom, H., Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 15 (2017), 1461–1468.
83. Adams, L.A., Anstee, Q.M., Tilg, H., Targher, G., Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66 (2017), 1138–1153.
84. Lonardo, A., Sookoian, S., Pirola, C.J., Targher, G., Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metab Clin Exp 65 (2016), 1136–1150.
85. Targher, G., Day, C.P., Bonora, E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363 (2010), 1341–1350.
86. Targher, G., Byrne, C.D., Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. Semin Thromb Hemost 39 (2013), 214–228.
87. Targher, G., Bertolini, L., Padovani, R., Zenari, L., Zoppini, G., Falezza, G., Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27 (2004), 2498–2500.
88. Brea, A., Mosquera, D., Martin, E., Arizti, A., Cordero, J.L., Ros, E., Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25 (2005), 1045–1050.
89. Volzke, H., Robinson, D.M., Kleine, V., Deutscher, R., Hoffmann, W., Ludemann, J., et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 11 (2005), 1848–1853.
90. Cai, J., Zhang, S., Huang, W., Association between nonalcoholic fatty liver disease and carotid atherosclerosis: a meta-analysis. Int J Clin Exp Med 8 (2015), 7673–7678.
91. Fracanzani, A.L., Burdick, L., Raselli, S., Pedotti, P., Grigore, L., Santorelli, G., et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 121 (2008), 72–78.
92. Wu, S., Wu, F., Ding, Y., Hou, J., Bi, J., Zhang, Z., Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep, 6, 2016, 33386.
93. Jepsen, P., Vilstrup, H., Mellemkjaer, L., Thulstrup, A.M., Olsen, J.H., Baron, J.A., et al. Prognosis of patients with a diagnosis of fatty liver–a registry-based cohort study. Hepatogastroenterology 50 (2003), 2101–2104.
94. Dunn, W., Xu, R., Wingard, D.L., Rogers, C., Angulo, P., Younossi, Z.M., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 103 (2008), 2263–2271.
95. Lonardo, A., Lombardini, S., Scaglioni, F., Ballestri, S., Verrone, A.M., Bertolotti, M., et al. Fatty liver, carotid disease and gallstones: a study of age-related associations. World J Gastroenterol 12 (2006), 5826–5833.
96. Dam-Larsen, S., Franzmann, M., Andersen, I.B., Christoffersen, P., Jensen, L.B., Sorensen, T.I., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53 (2004), 750–755.
97. Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.
98. Ekstedt, M., Franzen, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006), 865–873.
99. Targher, G., Bertolini, L., Rodella, S., Tessari, R., Zenari, L., Lippi, G., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30 (2007), 2119–2121.
100. Hamaguchi, M., Kojima, T., Takeda, N., Nagata, C., Takeda, J., Sarui, H., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13 (2007), 1579–1584.
101. Haring, R., Wallaschofski, H., Nauck, M., Dorr, M., Baumeister, S.E., Volzke, H., Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 50 (2009), 1403–1411.
102. Rafiq, N., Bai, C., Fang, Y., Srishord, M., McCullough, A., Gramlich, T., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 7 (2009), 234–238.
103. Soderberg, C., Stal, P., Askling, J., Glaumann, H., Lindberg, G., Marmur, J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51 (2010), 595–602.
104. Lazo, M., Hernaez, R., Bonekamp, S., Kamel, I.R., Brancati, F.L., Guallar, E., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ, 343, 2011, d6891.
105. Zhou, Y.J., Li, Y.Y., Nie, Y.Q., Huang, C.M., Cao, C.Y., Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis 13 (2012), 153–160.
106. Treeprasertsuk, S., Leverage, S., Adams, L.A., Lindor, K.D., St Sauver, J., Angulo, P., The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 32 (2012), 945–950.
107. Stepanova, M., Younossi, Z.M., Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10 (2012), 646–650.
108. El Azeem, H.A., Khalek el, S.A., El-Akabawy, H., Naeim, H., Khalik, H.A., Alfifi, A.A., Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J Saudi Heart Assoc 25 (2013), 239–246.
109. Kim, D., Kim, W.R., Kim, H.J., Therneau, T.M., Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57 (2013), 1357–1365.
110. Pisto, P., Santaniemi, M., Bloigu, R., Ukkola, O., Kesaniemi, Y.A., Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open, 4, 2014, e004973.
111. Moon, S.H., Noh, T.S., Cho, Y.S., Hong, S.P., Hyun, S.H., Choi, J.Y., et al. Association between nonalcoholic fatty liver disease and carotid artery inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography. Angiology 66 (2015), 472–480.
112. Wong, V.W., Wong, G.L., Yeung, J.C., Fung, C.Y., Chan, J.K., Chang, Z.H., et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology 63 (2016), 754–763.
113. Zeb, I., Li, D., Budoff, M.J., Katz, R., Lloyd-Jones, D., Agatston, A., et al. Nonalcoholic fatty liver disease and incident cardiac events: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol 67 (2016), 1965–1966.
114. Fracanzani, A.L., Tiraboschi, S., Pisano, G., Consonni, D., Baragetti, A., Bertelli, C., et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 246 (2016), 208–213.
115. Mantovani, A., Mingolla, L., Rigolon, R., Pichiri, I., Cavalieri, V., Zoppini, G., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int J Cardiol 225 (2016), 387–391.
116. Yoshitaka, H., Hamaguchi, M., Kojima, T., Fukuda, T., Ohbora, A., Fukui, M., Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study. Medicine, 96, 2017, e6712.
117. Kim, J., Lee, D.Y., Park, S.E., Park, C.Y., Lee, W.Y., Oh, K.W., et al. Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation. PLoS One, 12, 2017, e0180118.
118. Sinn, D.H., Kang, D., Chang, Y., Ryu, S., Gu, S., Kim, H., et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut 66 (2017), 323–329.
119. Park, H.E., Kwak, M.S., Kim, D., Kim, M.K., Cha, M.J., Choi, S.Y., Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study. J Clin Endocrinol Metab 101 (2016), 3134–3143.
120. Sinn, D.H., Cho, S.J., Gu, S., Seong, D., Kang, D., Kim, H., et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology 151 (2016), 481–488 e481.
121. Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397 e310.
122. Mantovani, A., Ballestri, S., Lonardo, A., Targher, G., Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig Dis Sci 61 (2016), 1246–1267.
123. Targher, G., Non-alcoholic fatty liver disease as driving force in coronary heart disease?. Gut 66 (2017), 213–214.
124. Lonardo, A., Ballestri, S., Targher, G., Loria, P., Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 9 (2015), 629–650.
125. Lonardo, A., Ballestri, S., Targher, G., “Not all forms of NAFLD were created equal”. Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?. Atherosclerosis 257 (2017), 253–255.
126. Miyaaki, H., Ichikawa, T., Nakao, K., Yatsuhashi, H., Furukawa, R., Ohba, K., et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 28 (2008), 519–524.
127. Hossain, N., Afendy, A., Stepanova, M., Nader, F., Srishord, M., Rafiq, N., et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7 (2009), 1224–1229 e1221–e1222.
128. Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34 (2001), 745–750.
129. Ono, M., Ochi, T., Munekage, K., Ogasawara, M., Hirose, A., Nozaki, Y., et al. Angiotensinogen gene haplotype is associated with the prevalence of Japanese non-alcoholic steatohepatitis. Hepatol Res 41 (2011), 1223–1229.
130. Yoneda, M., Hotta, K., Nozaki, Y., Endo, H., Uchiyama, T., Mawatari, H., et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int 29 (2009), 1078–1085.
131. Pelusi, S., Petta, S., Rosso, C., Borroni, V., Fracanzani, A.L., Dongiovanni, P., et al. Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression: an observational study in patients with nonalcoholic fatty liver disease. PLoS One, 11, 2016, e0163069.
132. Namisaki, T., Noguchi, R., Moriya, K., Kitade, M., Aihara, Y., Douhara, A., et al. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. J Gastroenterol 51 (2016), 162–172.
133. Aihara, Y., Yoshiji, H., Noguchi, R., Kaji, K., Namisaki, T., Shirai, Y., et al. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. Hepatol Res 43 (2013), 1241–1250.
134. Kato, J., Koda, M., Kishina, M., Tokunaga, S., Matono, T., Sugihara, T., et al. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. Int J Mol Med 30 (2012), 107–113.
135. Sturzeneker, M.C., Ioshii, S.O., Villela Baroncini, L.A., Precoma, D.B., Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia. Atherosclerosis 216 (2011), 97–102.
136. Noguchi, R., Yoshiji, H., Ikenaka, Y., Kaji, K., Shirai, Y., Aihara, Y., et al. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int J Mol Med 26 (2010), 407–413.
137. Fan, J.G., Li, F., Cai, X.B., Peng, Y.D., Ao, Q.H., Gao, Y., Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 22 (2007), 1086–1091.
138. Cai, D., Yuan, M., Frantz, D.F., Melendez, P.A., Hansen, L., Lee, J., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11 (2005), 183–190.
139. Bhagat, B., Burke, W.J., Dhalla, N.S., Insulin-induced enhancement of uptake of noradrenaline in atrial strips. Br J Pharmacol 74 (1981), 325–332.
140. Artunc, F., Schleicher, E., Weigert, C., Fritsche, A., Stefan, N., Haring, H.U., The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol 12 (2016), 721–737.
141. Aizawa-Abe, M., Ogawa, Y., Masuzaki, H., Ebihara, K., Satoh, N., Iwai, H., et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 105 (2000), 1243–1252.
142. Beltowski, J., Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 24 (2006), 789–801.
143. Rojas, E., Rodriguez-Molina, D., Bolli, P., Israili, Z.H., Faria, J., Fidilio, E., et al. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep, 16, 2014, 463.
144. Yoo, H.J., Choi, K.M., Hepatokines as a link between obesity and cardiovascular diseases. Diabetes Metab J 39 (2015), 10–15.
145. Takeuchi, M., Takino, J., Sakasai-Sakai, A., Takata, T., Ueda, T., Tsutsumi, M., et al. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol 6 (2014), 880–893.
146. Cannizzaro, L., Rossoni, G., Savi, F., Altomare, A., Marinello, C., Saethang, T., et al. Regulatory landscape of AGE-RAGE-oxidative stress axis and its modulation by PPARgamma activation in high fructose diet-induced metabolic syndrome. Nutr Metab, 14, 2017, 5.
147. Liu, Q., Chen, H.B., Luo, M., Zheng, H., Serum soluble RAGE level inversely correlates with left ventricular hypertrophy in essential hypertension patients. Genet Mol Res, 15, 2016.
148. Apovian, C.M., Bigornia, S., Mott, M., Meyers, M.R., Ulloor, J., Gagua, M., et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 28 (2008), 1654–1659.
149. Stanton, M.C., Chen, S.C., Jackson, J.V., Rojas-Triana, A., Kinsley, D., Cui, L., et al. Inflammatory Signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice. J Inflamm, 8, 2011, 8.
150. Villanova, N., Moscatiello, S., Ramilli, S., Bugianesi, E., Magalotti, D., Vanni, E., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 (2005), 473–480.
151. Dharmashankar, K., Widlansky, M.E., Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep 12 (2010), 448–455.
152. Benjamin, E.J., Larson, M.G., Keyes, M.J., Mitchell, G.F., Vasan, R.S., Keaney, J.F. Jr, et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 109 (2004), 613–619.
153. Kozono, M., Uto, H., Ibusuki, R., Arima, S., Oda, K., Taguchi, H., et al. Antihypertensive therapy improves insulin resistance and serum levels of interleukin-6 and -10 in spontaneously hypertensive rats with steatohepatitis. Mol Med Rep 14 (2016), 5385–5394.
154. Schwimmer, J.B., Zepeda, A., Newton, K.P., Xanthakos, S.A., Behling, C., Hallinan, E.K., et al. Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. PLoS One, 9, 2014, e112569.
155. Pasarin, M., La Mura, V., Gracia-Sancho, J., Garcia-Caldero, H., Rodriguez-Vilarrupla, A., Garcia-Pagan, J.C., et al. Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS One, 7, 2012, e32785.
156. Sookoian, S., Gianotti, T.F., Rosselli, M.S., Burgueno, A.L., Castano, G.O., Pirola, C.J., Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 218 (2011), 378–385.
157. Sigala, B., McKee, C., Soeda, J., Pazienza, V., Morgan, M., Lin, C.I., et al. Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells. PLoS One, 8, 2013, e72928.
158. Moreno, M.U., Eiros, R., Gavira, J.J., Gallego, C., Gonzalez, A., Ravassa, S., et al. The hypertensive myocardium: from microscopic lesions to clinical complications and outcomes. Med Clin North Am 101 (2017), 43–52.
159. Singh, I., Ma, K.C., Berlin, D.A., Pathophysiology of pulmonary hypertension in chronic parenchymal lung disease. Am J Med 129 (2016), 366–371.
160. O'Toole, J.F., Sedor, J.R., Kidney disease: new technologies translate mechanisms to cure. J Clin Invest 124 (2014), 2294–2298.
161. Lee, Y.H., Kim, S.U., Song, K., Park, J.Y., Kim, D.Y., Ahn, S.H., et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: nationwide surveys (KNHANES 2008–2011). Hepatology 63 (2016), 776–786.
162. Lee, Y.H., Jung, K.S., Kim, S.U., Yoon, H.J., Yun, Y.J., Lee, B.W., et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008–2011). J Hepatol 63 (2015), 486–493.
163. Hong, H.C., Hwang, S.Y., Choi, H.Y., Yoo, H.J., Seo, J.A., Kim, S.G., et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean sarcopenic obesity study. Hepatology 59 (2014), 1772–1778.
164. Brunkwall, L., Orho-Melander, M., The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. Diabetologia 60 (2017), 943–951.
165. Rubino, F., Forgione, A., Cummings, D.E., Vix, M., Gnuli, D., Mingrone, G., et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244 (2006), 741–749.
166. Erridge, C., Diet, commensals and the intestine as sources of pathogen-associated molecular patterns in atherosclerosis, type 2 diabetes and non-alcoholic fatty liver disease. Atherosclerosis 216 (2011), 1–6.
167. Moreira, A.P., Texeira, T.F., Ferreira, A.B., Peluzio Mdo, C., Alfenas, Rde C., Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr 108 (2012), 801–809.
168. Kim, K.A., Gu, W., Lee, I.A., Joh, E.H., Kim, D.H., High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One, 7, 2012, e47713.
169. Cani, P.D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58 (2009), 1091–1103.
170. Samuel, V.T., Shulman, G.I., The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 126 (2016), 12–22.
171. Bril, F., Sninsky, J.J., Baca, A.M., Superko, H.R., Portillo Sanchez, P., Biernacki, D., et al. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab 101 (2016), 644–652.
172. Mathis, D., Immunological goings-on in visceral adipose tissue. Cell Metab 17 (2013), 851–859.
173. Lumeng, C.N., Bodzin, J.L., Saltiel, A.R., Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117 (2007), 175–184.
174. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante, A.W. Jr., Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 (2003), 1796–1808.
175. Patsouris, D., Li, P.P., Thapar, D., Chapman, J., Olefsky, J.M., Neels, J.G., Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 8 (2008), 301–309.
176. Seijkens, T., Kusters, P., Chatzigeorgiou, A., Chavakis, T., Lutgens, E., Immune cell crosstalk in obesity: a key role for costimulation?. Diabetes 63 (2014), 3982–3991.
177. Hotamisligil, G.S., Inflammation, metaflammation and immunometabolic disorders. Nature 542 (2017), 177–185.
178. Petersen, M.C., Madiraju, A.K., Gassaway, B.M., Marcel, M., Nasiri, A.R., Butrico, G., et al. Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. J Clin Invest 126 (2016), 4361–4371.
179. Kumashiro, N., Erion, D.M., Zhang, D., Kahn, M., Beddow, S.A., Chu, X., et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 108 (2011), 16381–16385.
180. Lonardo, A., Lombardini, S., Scaglioni, F., Carulli, L., Ricchi, M., Ganazzi, D., et al. Hepatic steatosis and insulin resistance: does etiology make a difference?. J Hepatol 44 (2006), 190–196.
181. Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008), 1461–1465.
182. Kantartzis, K., Peter, A., Machicao, F., Machann, J., Wagner, S., Konigsrainer, I., et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58 (2009), 2616–2623.
183. Amaro, A., Fabbrini, E., Kars, M., Yue, P., Schechtman, K., Schonfeld, G., et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 139 (2010), 149–153.
184. Kozlitina, J., Boerwinkle, E., Cohen, J.C., Hobbs, H.H., Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 53 (2011), 467–474.
185. Sun, Z., Lazar, M.A., Dissociating fatty liver and diabetes. Trends Endocrinol Metab 24 (2013), 4–12.
186. Noto, D., Arca, M., Tarugi, P., Cefalu, A.B., Barbagallo, C.M., Averna, M.R., Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature. Acta Diabetol 54 (2017), 111–122.
187. Albert, J.S., Yerges-Armstrong, L.M., Horenstein, R.B., Pollin, T.I., Sreenivasan, U.T., Chai, S., et al. Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. N Engl J Med 370 (2014), 2307–2315.
188. Hsiao, P.J., Chen, Z.C., Hung, W.W., Yang, Y.H., Lee, M.Y., Huang, J.F., et al. Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C∗G) in the development of fatty liver. BMC Med Genet, 14, 2013, 54.
189. Chaurasia, B., Summers, S.A., Ceramides – Lipotoxic inducers of metabolic disorders. Trends Endocrinol Metab 26 (2015), 538–550.
190. Luukkonen, P.K., Zhou, Y., Sadevirta, S., Leivonen, M., Arola, J., Oresic, M., et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1167–1175.
191. Meex, R.C., Hoy, A.J., Morris, A., Brown, R.D., Lo, J.C., Burke, M., et al. Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism. Cell Metab 22 (2015), 1078–1089.
192. Al Rifai, M., Silverman, M.G., Nasir, K., Budoff, M.J., Blankstein, R., Szklo, M., et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 239 (2015), 629–633.
193. Fargion, S., Porzio, M., Fracanzani, A.L., Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol 20 (2014), 13306–13324.
194. Iacobellis, G., Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol 11 (2015), 363–371.
195. Kwon, H.M., Sangiorgi, G., Ritman, E.L., McKenna, C., Holmes, D.R. Jr., Schwartz, R.S., et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 101 (1998), 1551–1556.
196. Kuwahara, F., Kai, H., Tokuda, K., Shibata, R., Kusaba, K., Tahara, N., et al. Hypoxia-inducible factor-1alpha/vascular endothelial growth factor pathway for adventitial vasa vasorum formation in hypertensive rat aorta. Hypertension 39 (2002), 46–50.
197. Jaipersad, A.S., Lip, G.Y., Silverman, S., Shantsila, E., The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol 63 (2014), 1–11.
198. O'Brien, K.D., McDonald, T.O., Chait, A., Allen, M.D., Alpers, C.E., Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 93 (1996), 672–682.
199. Coulon, S., Legry, V., Heindryckx, F., Van Steenkiste, C., Casteleyn, C., Olievier, K., et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology 57 (2013), 1793–1805.
200. Lefere, S., Van de Velde, F., Devisscher, L., Bekaert, M., Raevens, S., Verhelst, X., et al. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. Int J Obes 41 (2017), 1207–1213.
201. Price, P.A., Lim, J.E., The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 278 (2003), 22144–22152.
202. Naito, C., Hashimoto, M., Watanabe, K., Shirai, R., Takahashi, Y., Kojima, M., et al. Facilitatory effects of fetuin-A on atherosclerosis. Atherosclerosis 246 (2016), 344–351.
203. Sato, M., Kamada, Y., Takeda, Y., Kida, S., Ohara, Y., Fujii, H., et al. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int 35 (2015), 925–935.
204. Eleftheriadou, I., Grigoropoulou, P., Kokkinos, A., Mourouzis, I., Perrea, D., Katsilambros, N., et al. Association of plasma fetuin-a levels with peripheral arterial disease and lower extremity arterial calcification in subjects with type 2 diabetes mellitus. J Diabetes Complications 31 (2017), 599–604.
205. Puri, P., Wiest, M.M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H.K., et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50 (2009), 1827–1838.
206. Kopprasch, S., Dheban, S., Schuhmann, K., Xu, A., Schulte, K.M., Simeonovic, C.J., et al. Detection of independent associations of plasma lipidomic parameters with insulin sensitivity indices using data mining methodology. PLoS One, 11, 2016, e0164173.
207. Sanyal, A.J., Pacana, T., A lipidomic readout of disease progression in a diet-induced mouse model of nonalcoholic fatty liver disease. Trans Am Clin Climatol Assoc 126 (2015), 271–288.
208. Van Rooyen, D.M., Larter, C.Z., Haigh, W.G., Yeh, M.M., Ioannou, G., Kuver, R., et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 141 (2011), 1393–1403 e1391–e1395.
209. Gan, L.T., Van Rooyen, D.M., Koina, M.E., McCuskey, R.S., Teoh, N.C., Farrell, G.C., et al. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J Hepatol 61 (2014), 1376–1384.
210. Van Rooyen, D.M., Gan, L.T., Yeh, M.M., Haigh, W.G., Larter, C.Z., Ioannou, G., et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 59 (2013), 144–152.
211. Zelber-Sagi, S., Azar, S., Nemirovski, A., Webb, M., Halpern, Z., Shibolet, O., et al. Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease. Obesity 25 (2017), 94–101.
212. Green, C.L., Mitchell, S.E., Derous, D., Wang, Y., Chen, L., Han, J.J., et al. The effects of graded levels of calorie restriction: IX. Global metabolomic screen reveals modulation of carnitines, sphingolipids and bile acids in the liver of C57BL/6 mice. Aging Cell 16 (2017), 529–540.
213. Vorkas, P.A., Shalhoub, J., Isaac, G., Want, E.J., Nicholson, J.K., Holmes, E., et al. Metabolic phenotyping of atherosclerotic plaques reveals latent associations between free cholesterol and ceramide metabolism in atherogenesis. J Proteome Res 14 (2015), 1389–1399.
214. Cheng, J.M., Suoniemi, M., Kardys, I., Vihervaara, T., de Boer, S.P., Akkerhuis, K.M., et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. Atherosclerosis 243 (2015), 560–566.
215. Park, J.Y., Lee, S.H., Shin, M.J., Hwang, G.S., Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction. PLoS One, 10, 2015, e0135228.
216. Vorkas, P.A., Shalhoub, J., Lewis, M.R., Spagou, K., Want, E.J., Nicholson, J.K., et al. Metabolic phenotypes of carotid atherosclerotic plaques relate to stroke risk: an exploratory study. Eur J Vasc Endovascular Surg 52 (2016), 5–10.